Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
about
Hijacking PrP(c)-dependent signal transduction: when prions impair Aβ clearanceEffects of FlAsH/tetracysteine (TC) Tag on PrP proteolysis and PrPres formation by TC-scanning.Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum diffFrom high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease.Genetic cross-interaction between APOE and PRNP in sporadic Alzheimer's and Creutzfeldt-Jakob diseases.Cellular prion protein expression is not regulated by the Alzheimer's amyloid precursor protein intracellular domain.A common BACE1 polymorphism is a risk factor for sporadic Creutzfeldt-Jakob diseaseTherapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie.PrPC Undergoes Basal to Apical Transcytosis in Polarized Epithelial MDCK CellsMorphine Withdrawal Modifies Prion Protein Expression in Rat HippocampusSeparate mechanisms act concurrently to shed and release the prion protein from the cell.Genetic variability of the gene cluster CALHM 1-3 in sporadic Creutzfeldt-Jakob disease.Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapieGlycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry.Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfoldingCytoplasmic inclusions of TDP-43 in neurodegenerative diseases: a potential role for caspases.α-Secretase-derived cleavage of cellular prion yields biologically active catabolites with distinct functions.The P's and Q's of cellular PrP-Aβ interactionsAmyloid-β Activates Microglia and Regulates Protein Expression in a Manner Similar to Prions.Unraveling the neuroprotective mechanisms of PrP (C) in excitotoxicity.The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity.Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes.Two-steps control of cellular prion physiology by the extracellular regulated kinase-1 (ERK1)The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivoThe beta amyloid peptide can act as a modular aggregation domain.Developmental influence of the cellular prion protein on the gene expression profile in mouse hippocampus.PrP(106-126) activates neuronal intracellular kinases and Egr1 synthesis through activation of NADPH-oxidase independently of PrPc.Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils.La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease.Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro.Alzheimer's and prion diseases: PDK1 at the crossroads.
P2860
Q27009790-8FB18554-6170-4622-9578-D8794647C84AQ30352829-A218C4E7-4F2C-4A7C-BCAE-052F74BFE3E1Q30416813-23A21A35-ADC3-42D1-994D-F0179D2B636AQ31023317-DD3B5C25-4390-454E-890E-F3AE304E7CEDQ31026808-992040FB-E66F-4D20-A0B5-6AE5E67F427AQ34171325-F4DFFAE9-7983-4C23-AAD8-81FC5FF572D8Q34405864-EEFE0045-42B2-4CFF-AE98-AECDAEFF5692Q35918940-3C2A8F0F-7574-4816-B557-186157C046CCQ36070581-8AE5DDC4-D5E1-4E45-9194-BC89CB1A9430Q36247645-D060C6AB-EB81-46C4-9A01-400409F00D95Q36436218-86B2B9F5-F30B-4784-ACBE-34D13349862FQ36719069-798BB28F-69A2-4039-9054-D96FAA0CF96DQ37250368-2B2321D8-B591-4078-BB7C-4DD8F0DCCB44Q37287652-731BB936-A7BA-4E48-BD2E-32862E4FFCB7Q37490746-25EBA91D-412D-4C88-90FE-ECB56DE093A8Q37530731-CAA972F5-D123-4F38-B2F5-3A5B5ACCB2B1Q37977276-4BF5B715-737B-414A-B849-E0284F4B3891Q38032986-5898DCF5-2BB1-4185-B53B-D98A0B444C2CQ38887770-8BC16CCC-7C6C-4A5C-911B-181EF1D2A256Q39638073-44925B70-5185-48D4-AAA8-FF670930BF37Q40360129-A58CE26E-D64D-45E9-BBA5-D97A77D08657Q41412807-555AF53E-F0A7-4185-A424-218781133AABQ41866781-F5C63AF9-8A86-40B0-9720-ADF12AA61B84Q42151993-64F28D3C-E4A9-4DB8-A449-1722430CCE1CQ43177076-0EF0EB39-3649-47F8-B9F3-D6DF93003772Q43798516-F894764A-9214-4F5A-856F-67675EF40466Q46603299-12358C93-7AE2-47E5-88D7-81CB5E0B51CFQ48158107-FF76FC1A-98D1-4770-8509-B8E8556A4DB3Q48396205-D96EAFEE-2A64-4159-9844-3227D8DFBFD3Q48881475-6068BBFB-4502-431C-A80B-E464D7620F7DQ53343627-B0963D88-AD4B-46E5-8F2B-6A23FE16ABB3
P2860
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
@ast
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
@en
type
label
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
@ast
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
@en
prefLabel
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
@ast
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
@en
P921
P1476
Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators
@en
P2093
Bruno Vincent
P304
P356
10.1016/S0166-2236(02)02263-4
P577
2002-12-01T00:00:00Z